- |||||||||| Lecigon (carbidopa/levodopa/entacapone) / LobSor, Comtan (entacapone) / Novartis, Orion Corp, APO-go (apomorphine continuous subcutaneous infusion) / Stada, Kyowa Kirin, Endo, Supernus Pharma
Review, Journal, Metastases: Should continuous dopaminergic stimulation be a standard of care in advanced Parkinson's disease? (Pubmed Central) - Nov 15, 2023
Clinical studies and real-life experience support the notion that infusion therapies should be accepted as part of the standard of care for patients with advanced PD who have refractory, severe, and disabling motor complications that affect their quality of life. However, they should be considered based on the needs of individualized patients and the access to these advanced therapies needs to be made more accessible to the general PD population.
- |||||||||| Journal, HEOR, Cost-effectiveness, Cost effectiveness: Cost-Effectiveness of Antiobesity Drugs for Adolescents With Severe Obesity. (Pubmed Central) - Nov 3, 2023
Metformin hydrochloride and 2 types of bariatric surgical procedures (sleeve gastrectomy and gastric bypass) were considered in sensitivity analysis...Orlistat and liraglutide cost more and were less effective than phentermine-topiramate and semaglutide, respectively...In this economic evaluation of weight loss drugs for adolescents with severe obesity, we found phentermine-topiramate to be a cost-effective treatment at a willingness-to-pay threshold of $100?000 to $150?000/QALY. Further research is needed to determine long-term drug efficacy and how long adolescents continue treatment.
- |||||||||| Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
Enrollment change, Trial withdrawal: Phentermine/Topiramate as Preventive Pharmacotherapy for Obesity (clinicaltrials.gov) - Oct 26, 2023
P2, N=0, Withdrawn,
Further research is needed to determine long-term drug efficacy and how long adolescents continue treatment. N=140 --> 0 | Not yet recruiting --> Withdrawn
- |||||||||| Inflectra (infliximab-dyyb) / Alvogen, Celltrion, Mundipharma, Egis, Nippon Kayaku, Pfizer
Observational data, Journal, Real-world evidence, Real-world: Real-World Safety and Efficacy of Biosimilar CT-P13 in Patients with Immune-Mediated Inflammatory Diseases: Integrated Analysis of Three Japanese Prospective Observational Studies. (Pubmed Central) - Oct 22, 2023
The integrated analysis of a large number of patients detected no new safety signals with long-term CT-P13 treatment. Efficacy in rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis cases was confirmed in biologic-na
- |||||||||| Comtan (entacapone) / Novartis, Orion Corp, sunitinib / Generic mfg.
Trial completion, Combination therapy, Stroma: Entacapone Combination With Imatinib for Treatment of GIST (clinicaltrials.gov) - Oct 18, 2023
P1, N=5, Completed,
Efficacy in rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis cases was confirmed in biologic-na Active, not recruiting --> Completed
- |||||||||| Symlin (pramlintide) / AstraZeneca, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen, Xenical (orlistat) / Roche, GSK
Review, Journal: Treating obesity in type 1 diabetes mellitus - review of efficacy and safety. (Pubmed Central) - Oct 11, 2023
Treatments also have varying adverse effect profiles which may impact T1D treatment. In this review, we aim to summarize study outcomes in people with T1D, including risks and benefits, of on- and off-label weight loss treatments.
- |||||||||| phentermine / Generic mfg.
Journal: The Use of Phentermine for Obesity in Psychiatric Patients With Antipsychotics. (Pubmed Central) - Oct 5, 2023
In this review, we aim to summarize study outcomes in people with T1D, including risks and benefits, of on- and off-label weight loss treatments. Overall, phentermine was effective and tolerable for patients with obesity taking antipsychotic medications, and ACT (predominantly topiramate) augmented the weight-loss effect of phentermine.
- |||||||||| Saxenda (liraglutide 3 mg) / Novo Nordisk
Enrollment open, Trial completion date: Anti-obesity Pharmacotherapy and Inflammation (clinicaltrials.gov) - Oct 4, 2023
P=N/A, N=24, Recruiting,
Overall, phentermine was effective and tolerable for patients with obesity taking antipsychotic medications, and ACT (predominantly topiramate) augmented the weight-loss effect of phentermine. Not yet recruiting --> Recruiting | Trial completion date: Jan 2024 --> Apr 2024
- |||||||||| Inflectra (infliximab-dyyb) / Alvogen, Celltrion, Mundipharma, Egis, Nippon Kayaku, Pfizer, Zymfentra (infliximab-dyyb subcutaneous) / Celltrion
Enrollment open: PRIME: IBD Disease Course of Infliximab-na (clinicaltrials.gov) - Oct 3, 2023
P=N/A, N=120, Recruiting,
Not yet recruiting --> Recruiting | Trial completion date: Jan 2024 --> Apr 2024 Not yet recruiting --> Recruiting
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen, Xenical (orlistat) / Roche, GSK
Review, Journal: Shedding light on weight loss: A narrative review of medications for treating obesity. (Pubmed Central) - Sep 27, 2023
The benefit-to-risk of medications, comorbidities, and individual responses should guide the treatment decisions. The article provides a comprehensive overview and discussion of several weight loss medications used previously and currently, including their efficacy, mechanisms of action, and side effects.
- |||||||||| Comtan (entacapone) / Novartis, Orion Corp, Ongentys (opicapone) / Ono Pharma, Neurocrine, BIAL
Journal: Patients' Preferences for Adjunctive Parkinson's Disease Treatments: A Discrete-Choice Experiment. (Pubmed Central) - Sep 19, 2023
The attributes and levels selected for this study were intended to reflect the characteristics of opicapone and entacapone; attributes associated with other adjunctive therapies were not evaluated. Patients with PD expressed interest in adjunctive treatment to increase ON time and would accept reduced ON time to avoid adverse effects.
- |||||||||| Review, Journal: A narrative review of approved and emerging anti-obesity medications. (Pubmed Central) - Sep 15, 2023
The use of AOM increased enormously despite its sometimes-dubious safety and ineffectiveness. The public and medical professionals should be vigilant to the real-world benefits of anti-obesity drugs and their achieved effectiveness with an improved safety profile.
- |||||||||| Comtan (entacapone) / Novartis, Orion Corp
Journal: Small-Molecule Drug Repurposing for Counteracting Phototoxic A2E Aggregation. (Pubmed Central) - Sep 14, 2023
In-depth mechanistic analysis suggests that entacapone prevents the conversion of toxic aggregates by redirecting A2E into off-pathway oligomers. These findings provide evidence that aggregation contributes to the phototoxicity of A2E.
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
Journal, HEOR, Cost-effectiveness, Cost effectiveness: Cost-Effectiveness of Pharmacotherapy for the Treatment of Obesity in Adolescents. (Pubmed Central) - Aug 31, 2023
In this economic evaluation of pharmacotherapy for adolescents with obesity, top-dose phentermine and topiramate as adjunct to lifestyle counseling was estimated to be cost-effective after 5 years. Long-term clinical trials in adolescents are needed to fully evaluate the outcomes of pharmacotherapy, especially into adulthood.
- |||||||||| Comtan (entacapone) / Novartis, Orion Corp
Levodopa-entacapone-carbidopa-infusion treatment in Parkinson () - Aug 30, 2023 - Abstract #MDSCongress2023MDS_Congress_1587;
Long-term clinical trials in adolescents are needed to fully evaluate the outcomes of pharmacotherapy, especially into adulthood. Objective: Objectives of this study were to evaluate changes in medication, adverse events and early discontinuations of levodopa-entacapone-carbidopa-intestinal-gel (LECIG) treatment in advanced Parkinson
- |||||||||| Lecigon (carbidopa/levodopa/entacapone) / LobSor, Comtan (entacapone) / Novartis, Orion Corp
Clinical Improvement and drastic reduction of Equivalent Dose of Levodopa (LEDD) in an Advanced Parkinson (Auditorium 10-11 (First floor)) - Aug 30, 2023 - Abstract #MDSCongress2023MDS_Congress_1582;
LECIG is a new available option in advanced PD patients. Our patient with severe GI dysmotility benefited from receiving this direct intraduodenal therapy, with no adverse effects, major improvement in her symptoms and an important reduction in total LEDD.
- |||||||||| Lecigon (carbidopa/levodopa/entacapone) / LobSor, Comtan (entacapone) / Novartis, Orion Corp
Levodopa-entacapone-carbidopa intestinal gel infusion for Parkinson () - Aug 30, 2023 - Abstract #MDSCongress2023MDS_Congress_1562;
With more than 3 years of clinical experience with LECIG in 150 patients, we conclude that LECIG is a viable alternative for the management of advanced PD. Long-term efficacy and tolerability of LECIG need to be further investigated.
- |||||||||| Comtan (entacapone) / Novartis, Orion Corp, Ongentys (opicapone) / Ono Pharma, Neurocrine, BIAL
Combination COMT inhibitor with Levodopa reduces consumption of vitamin B6 () - Aug 30, 2023 - Abstract #MDSCongress2023MDS_Congress_1547;
The authors hypothesized that high COMT activity would result in elevated homocysteine and declined vitamin B6, vitamin B12 and folate, and that concomitant use of COMT-I would suppress these changes.; We compared pharmacokinetics of LD and 3-OMD with those of vitamin B6, vitamin B12, folate, and homocysteine in 110 PD patients (49 males and 61 females) attending our institution during oral administration of fixed-dose LD/DCI, with and without oral COMT-I (Entacapone and Opicapone). Our comparative study of LD and 3-OMD pharmacokinetics and vitamin levels in Japanese PD patients with and without concomitant COMT-I during oral administration of LD/DCI combination drugs revealed that vitamin B6 decreased with higher daily LD dose though concomitant use of a COMT-I reduced vitamin B6 consumption.
- |||||||||| Comtan (entacapone) / Novartis, Orion Corp, Ongentys (opicapone) / Ono Pharma, Neurocrine, BIAL
Opicapone versus entacapone: Head-to-head comparison of Healthcare Resource Utilisation in COMT-I na () - Aug 30, 2023 - Abstract #MDSCongress2023MDS_Congress_1543;
Our comparative study of LD and 3-OMD pharmacokinetics and vitamin levels in Japanese PD patients with and without concomitant COMT-I during oral administration of LD/DCI combination drugs revealed that vitamin B6 decreased with higher daily LD dose though concomitant use of a COMT-I reduced vitamin B6 consumption. This head-to-head study is the first to demonstrate using
- |||||||||| Lecigon (carbidopa/levodopa/entacapone) / LobSor, Comtan (entacapone) / Novartis, Orion Corp
Levodopa-Entacapone-Carbidopa Intestinal Gel in advanced Parkinson () - Aug 30, 2023 - Abstract #MDSCongress2023MDS_Congress_1530;
This head-to-head study is the first to demonstrate using Most patients (81.2%) were also being treated with dopamine agonists, namely pramipexole (3 patients, 18.6%; mean dose 2.4
- |||||||||| Comtan (entacapone) / Novartis, Orion Corp, Xadago (safinamide) / Meiji Seika, Eisai, Valeo Pharma, Zambon, Supernus Pharma
Dopamine dysregulation syndrome in Parkinson () - Aug 30, 2023 - Abstract #MDSCongress2023MDS_Congress_613;
DDS is a rare but difficult to manage. We suggest the safinamide can be a way to control DDS through this case.
- |||||||||| Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
Review, Journal: A Narrative Review: Phentermine and Topiramate for the Treatment of Pediatric Obesity. (Pubmed Central) - Aug 29, 2023
In 2022, the phentermine/topiramate (PHEN/TPM), once-daily, controlled-release, combination product received FDA approval, for the indication of chronic weight management, in youth with obesity, ages 12 years and older. The objectives of this narrative review are to: (1) Review the mechanism of action of phentermine and topiramate, (2) Summarize the safety and efficacy data of topiramate and phentermine use as both monotherapies and in combination, and (3) Discuss clinical practice guidelines and clinical implications, for the use of these agents in youths with obesity.
- |||||||||| Inflectra (infliximab-dyyb) / Alvogen, Celltrion, Mundipharma, Egis, Nippon Kayaku, Pfizer
Review, Journal: Post-translational modifications comparative identification and kinetic study of infliximab innovator and biosimilars in serum using capillary electrophoresis-tandem mass spectrometry. (Pubmed Central) - Aug 28, 2023
The objectives of this narrative review are to: (1) Review the mechanism of action of phentermine and topiramate, (2) Summarize the safety and efficacy data of topiramate and phentermine use as both monotherapies and in combination, and (3) Discuss clinical practice guidelines and clinical implications, for the use of these agents in youths with obesity. Here, we identified and evaluated the modification kinetics of 4 asparagine deamidations and 2 aspartate isomerizations of infliximab innovator product (Remicade
- |||||||||| Journal, Real-world evidence, Adherence, Real-world: Real-world primary nonadherence to antiobesity medications. (Pubmed Central) - Aug 18, 2023
Dr Bengtson is employed at Boehringer Ingelheim Pharmaceuticals, Inc. (Boehringer Ingelheim has no connection to this study), and during the conduct of this study was employed at Optum.
- |||||||||| Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
Review, Journal: Current and future pharmacotherapies for obesity in children and adolescents. (Pubmed Central) - Aug 11, 2023
The importance of a comprehensive and chronic care model, including both lifestyle modification and ongoing pharmacotherapy, will be discussed in the context of maximizing long-term health outcomes. Finally, insight will be provided into the emerging pipeline of AOMs (for example, incretin receptor co-agonists and tri-agonists) and how future therapies might fundamentally change the prognosis for youth with obesity.
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen, Imcivree (setmelanotide) / Rhythm Pharma
Review, Journal: Pediatric Obesity: Complications and Current Day Management. (Pubmed Central) - Jul 29, 2023
Metabolic and bariatric surgery may be used for the management of severe obesity in youth; though highly effective, it is limited to specialized centers and has had relatively low pediatric uptake. In this narrative review using pediatric-focused data from original research, reviews, clinical practice guidelines, governmental agencies, and pharmaceutical companies, we review obesity-related metabolic complications in youth and management strategies, including AOM and bariatric surgery.
- |||||||||| Comtan (entacapone) / Novartis, Orion Corp
Clinical, Review, Journal: Catechol-O-methyl-transferase inhibition with entacapone: Evidence from controlled clinical trials in Parkinson's Disease. (Pubmed Central) - Jul 26, 2023
Entacapone can be a rare cause of lymphocytic colitis with severe diarrhoea and need for treatment discontinuation. In 2003 a triple combination pill of levodopa, carbidopa and entacapone (LCE) was first introduced into the market and since then proprietary LCE (Stalevo) is indicated on the basis of those trials for patients with idiopathic PD to: (1) substitute for immediate-release carbidopa/levodopa and entacapone previously administered as individual products; or (2) replace immediate-release carbidopa/levodopa therapy (without entacapone) when patients taking a total daily dose of levodopa <600 mg and not experiencing dyskinesias experience signs and symptoms of end-of-dose wearing off.
- |||||||||| entacapone/levodopa/carbidopa / Generic mfg.
Review, Journal, Real-world evidence, Real-world: Real-world considerations of the use of Stalevo in Parkinson's Disease. (Pubmed Central) - Jul 25, 2023
The hepatotoxicity observed with the class comparator tolcapone has not been observed with entacapone, the COMT inhibitor in LCE, and there is no formal requirement to monitor liver function during LCE therapy. Other common side effects include diarrhoea, which is one of the more prominent non-dopaminergic adverse events, and urine discolouration, which is harmless but about which patients may require reassurance.
- |||||||||| Comtan (entacapone) / Novartis, Orion Corp, Ongentys (opicapone) / Ono Pharma, Neurocrine, BIAL
Retrospective data, Journal, HEOR, Head-to-Head: Opicapone versus entacapone: Head-to-head retrospective data-based comparison of healthcare resource utilization in people with Parkinson's new to COMT inhibitor treatment. (Pubmed Central) - Jul 25, 2023
Other common side effects include diarrhoea, which is one of the more prominent non-dopaminergic adverse events, and urine discolouration, which is harmless but about which patients may require reassurance. This head-to-head study is the first to demonstrate using 'real-world' data that initiating COMT inhibition with opicapone is likely to decrease the need for post-treatment HCRU versus initiation of COMT inhibition with entacapone.
- |||||||||| Comtan (entacapone) / Novartis, Orion Corp
Journal: Case study on the treatment of dopamine dysregulation syndrome. (Pubmed Central) - Jul 18, 2023
This head-to-head study is the first to demonstrate using 'real-world' data that initiating COMT inhibition with opicapone is likely to decrease the need for post-treatment HCRU versus initiation of COMT inhibition with entacapone. Reducing the dosage of Madopar and reasonably applying the treatment regimen can improve the clinical treatment effect and improve the quality of life of patients.
- |||||||||| Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen, Xenical (orlistat) / Roche, GSK
Review, Journal: Renal Damage and Obesity: a Silent Pairing (Pubmed Central) - Jul 14, 2023
Bariatric surgery techniques that are generally divided into restrictive, malabsorptive, and mixed are not free from possible metabolic complications such as anemia, vitamin deficiency, and stones. However, they are able to ensure a good maintenance of weight loss obtained with disappearance or reduction of the incidence and severity of comorbidities related to obesity.
- |||||||||| Inflectra (infliximab-dyyb) / Alvogen, Celltrion, Mundipharma, Egis, Nippon Kayaku, Pfizer
Journal: Effectiveness of biosimilar infliximab CT-P13 compared to originator infliximab in biological-na (Pubmed Central) - Jul 12, 2023
However, they are able to ensure a good maintenance of weight loss obtained with disappearance or reduction of the incidence and severity of comorbidities related to obesity. There are no differences in effectiveness between the infliximab biosimilar CT-P13 and the infliximab originator in the treatment of biological-na
- |||||||||| Journal: Expanded table: Some drugs for inflammatory bowel disease. (Pubmed Central) - Jul 11, 2023
The fact that 1 generated a complex with SAH and COMT also suggests that 1 could inhibit COMT twofold, as a typical substrate mimic competitive inhibitor and as a product-inhibition enhancer. No abstract available
- |||||||||| Journal: Obesity prevalence and variability in management practices for patients with symptomatic peripheral artery disease. (Pubmed Central) - Jun 19, 2023
In conclusion, obesity is a prevalent modifiable comorbidity in PAD that is hardly addressed during PAD management, with significant variability across practices. As obesity prevalence rates are growing, along with treatment modalities to treat it, especially in those with PAD, building systems to integrate systematic evidence-based weight and dietary management strategies in PAD are essential to close this gap in care.
- |||||||||| Inflectra (infliximab-dyyb) / Alvogen, Celltrion, Mundipharma, Egis, Nippon Kayaku, Pfizer
PK/PD data, Journal: Comparison of the Pharmacokinetics of CT-P13 Between Crohn's Disease and Ulcerative Colitis. (Pubmed Central) - Jun 16, 2023
As obesity prevalence rates are growing, along with treatment modalities to treat it, especially in those with PAD, building systems to integrate systematic evidence-based weight and dietary management strategies in PAD are essential to close this gap in care. Infliximab shows more favorable pharmacokinetics, including high drug trough and low ADA levels, in CD than in UC, which might result in better clinical outcomes for 1-year infliximab treatment in CD patients.
- |||||||||| Comtan (entacapone) / Novartis, Orion Corp
Journal: Role of Molecular, Crystal, and Surface Chemistry in Directing the Crystallization of Entacapone Polymorphs on the Au(111) Template Surface. (Pubmed Central) - Jun 12, 2023
Infliximab shows more favorable pharmacokinetics, including high drug trough and low ADA levels, in CD than in UC, which might result in better clinical outcomes for 1-year infliximab treatment in CD patients. Molecular dynamics modeling of the entacapone/gold interface reveals the entacapone molecular structure within the first adsorbed layer to show nearly identical interaction distances, for both the molecules within form A or D with respect to the Au surface, while in the second and third layers when entacapone molecule-molecule interactions overtake the interactions between those of molecule-Au, the intermolecular structures are found to be closer to the form A structure than form D. In these layers, synthon G (form A) could be reproduced with just two small azimuthal rotations (5
|
